Founder Interview
How Febo Health Reached 14,000 App Downloads and Closed a $106K SAFE Round at a $4M Valuation (Interview with Chairman and Founder Nicholas Focil)
- Interview Date
- February 2, 2022
- Interviewee
- Nicholas FocilChairman and Founder
Company Metrics at Interview Time
SAFE Round 1 Valuation (2022)
$4,000,000
SAFE Round Raised (2022)
$106,000
App Downloads (2022)
14,000
Investor Equity (2022)
3%
Founder Equity (2022)
82%
Historical Snapshot
These numbers were reported by Nicholas Focil during his interview with Nathan Latka recorded in February 2022 and are a historical snapshot, not current figures. See Febo Health’s current numbers.

Key Takeaways
- 01Febo Health closed a $106,000 SAFE round at a $4,000,000 valuation, oversubscribed.
- 02The app had 14,000 downloads as of February 2022, launched on the App Store in June 2021.
- 03The company had zero revenue at interview time, with no plans to monetize for two to three years.
- 04Nicholas Focil owns 82% of Febo Health; the agency FOMAT Medical Research owns 5%; an ESOP pool accounts for 10%; and investors own 3%.
- 05FOMAT Medical Research invested an estimated $500,000 to $750,000 into Febo Health in exchange for 5% equity.
- 06The company estimated roughly 200 downloads per week just before launching paid advertising on February 1, 2022.
- 07Febo Health targets a minimum threshold of 100,000 users before opening monetization.
- 08Garmin reached out to Febo Health for a partnership, allowing Garmin device data to integrate into the app.
- 09Paid advertising launched on February 1, 2022, the day before the interview, with no spend yet from the $106,000 raise.
- 10Nicholas Focil is 35 years old and built Febo Health as a byproduct of his clinical research agency.
Company Metrics at Time of Interview
| Metric | Value | Source |
|---|---|---|
| SAFE Round 1 Valuation (2022) | $4,000,000 | Founder interview, Feb 2022 |
| SAFE Round 1 Raised (2022) | $106,000 | Founder interview, Feb 2022 |
| App Downloads (2022) | 14,000 | Founder interview, Feb 2022 |
| App Store Launch | June 2021 | Founder interview, Feb 2022 |
| Founder Equity (Nicholas Focil) (2022) | 82% | Founder interview, Feb 2022 |
| ESOP Pool (2022) | 10% | Founder interview, Feb 2022 |
| Investor Equity (SAFE Round 1) (2022) | 3% | Founder interview, Feb 2022 |
| Agency Equity (FOMAT Medical Research) (2022) | 5% | Founder interview, Feb 2022 |
| Agency Investment into Febo Health (estimated) (2022) | $500,000 to $750,000 | Founder interview, Feb 2022 |
| Estimated Weekly Downloads (pre-paid ads) (Feb 2022) | 200 | Founder interview, Feb 2022 |
| Revenue (2022) | $0 | Founder interview, Feb 2022 |
Growth Breakdown
Revenue
Febo Health had zero revenue at the time of the interview. Nicholas Focil stated the company is not looking to make money for the next two to three years and is entirely funded for growth.
App Downloads and Users
The app reached 14,000 downloads since its June 2021 App Store launch, growing entirely organically until February 1, 2022, when paid advertising was switched on. The team estimated roughly 200 downloads per week just before that launch.
Funding
The company closed a $106,000 raise at a $4,000,000 valuation on SAFE round one, which was oversubscribed. Prior to this raise, FOMAT Medical Research had invested an estimated $500,000 to $750,000 into the product in exchange for 5% equity.
Team and Ownership
Nicholas Focil holds 82% of Febo Health, with a 10% ESOP pool set aside for key employees, 3% held by SAFE round investors, and 5% held by FOMAT Medical Research. The company relies on a team Focil describes as top-notch, with employees holding equity stakes.
Growth Strategy
Organic App Store Growth
From June 2021 through January 2022, all 14,000 downloads came through entirely organic channels with no paid advertising spend from the raised capital.
Paid Advertising Launch
On February 1, 2022, the company turned on paid advertising for the first time using the newly closed SAFE round funds, expecting a significant uptick in downloads.
Flagship News Feed Tool
A patent-pending algorithm aggregates and translates condition-specific medical news from validated global sources and pushes it to users in real time, which Focil identified as the easiest tool to drive adoption and one of the app's flagship features.
Hardware Partnerships
Garmin reached out to Febo Health for a partnership, enabling Garmin device data to integrate directly into the app and pre-fill user health information, extending reach through existing wearable users.
Crowdsourced Anonymous Data
The app is built around fully anonymous, double-encrypted crowdsourcing of symptom and medication data, allowing chronic condition patients to compare their experiences with others and bring data-driven questions to their physicians.
Best Quotes
“Right now, it's entirely embedded. There's no revenue. There is we're not looking to make any money on it for about the next two to three years. It's entirely gonna be funded for for growth at this point.”
“It was a 106,000, safe round one at $4,000,000 valuation.”
“So this is a byproduct of my company, FOMAT Medical Research, the one I'm CEO for, and that's been it's a product of it. So it's been paying salaries.”
“I don't know. I don't have any direct number for you. I would I would guess somewhere in $500,000 to $750,000.”
“So I don't own 87. I own 82. The agency owns 5%.”
“So in two to three years, we'll start opening it up. We're looking to get to a minimum threshold about a 100,000 users.”
“I honestly have a phenomenal team. Like, it just, you know, top, top, top notch team. People that see the vision of this company, see the vision of the software, and obviously have some skin in the game as well.”
“Entirely anonymous, entirely encrypted, double encrypted. You don't need to even put a name to it. You don't need to put an email. Like, you don't even have to create you can you can have it be entirely fake where you can put a wall, like, can put a different picture. We don't request any information from you.”
What Happened Next
This interview captured Febo Health at a very early stage in February 2022, one day after the company switched on paid advertising for the first time and immediately after closing its first SAFE round. At that point the app had 14,000 downloads, zero revenue, and a planned two-to-three-year runway before any monetization. Visit the Febo Health company profile on GetLatka for current metrics and any updates since this recording.
View Febo Health’s current profile and metricsFull Transcript
Chapters
- 0:00Introduction: Nick Focil and Febo Health
- 0:27No Revenue: Entirely Funded for Growth
- 0:54SAFE Round: $106K at $4M Valuation
- 1:41Funding the Company Through FOMAT Medical Research
- 2:40Balancing the Agency and the SaaS Product
- 3:26Agency Investment Estimated at $500K to $750K
- 8:19One in Three Americans Live With a Chronic Condition
- 10:30Anonymous and Encrypted: Solving the Privacy Problem
- 11:4614,000 Downloads and the News Feed Flagship Tool
- 14:56Path to Monetization: 100,000 User Threshold
- 15:46Paid Advertising Launched February 1, 2022
- 17:10Cap Table Breakdown: Founder, Agency, ESOP, Investors
- 17:39Famous Five: Books, Sleep, and Lessons Learned
Introduction: Nick Focil and Febo Health
Nathan Latka
00:00Folks. My guest today is Nick Focil. He is the chairman and founder of febohealth toolbox SaaS app used globally by chronic condition patients to help make life a little easier. After obtaining his biochemistry degree, he worked in several positions and is the CEO of Fomat Medical Research in addition to his role at febo. Nick, ready to take us to the top?
Nicholas Focil
00:17>> Let's do it.
Nathan Latka
00:18Alright. So people wanna follow along. It's febohealth.com. Tell me who's paying for this product. How are they using it?
No Revenue: Entirely Funded for Growth
Nicholas Focil
00:27>> Right now, it's entirely embedded. There's no revenue. There is we're not looking to make any money on it for about the next two to three years. It's entirely gonna be funded for for growth at this point.
Nathan Latka
00:41Okay. So how are you paying bills? Have you raised a bunch of capital or what?
Nicholas Focil
00:45>> Yeah. We've been raising we've done we just finished our safe round. We oversubscribed it, actually. So we're pretty excited about that.
Nathan Latka
00:52How much did you raise?
SAFE Round: $106K at $4M Valuation
Nicholas Focil
00:54>> It was a 106,000, safe round one at $4,000,000 valuation.
01:01>> And the that was that will take us to a roughly about end of June, and then we're looking to raise safe round two. Our projection value at that point will be about 8,000,000. We're looking to about total between the first round, which was 3%. Second round is about gonna be 6%.
Nathan Latka
01:20Sorry. Second round is 56 percent of what?
Nicholas Focil
01:23>> 6%. 6%.
Nathan Latka
01:246%.
Nicholas Focil
01:25>> Yeah. A total of 9%.
Nathan Latka
01:27So so got it. So just speak when did you write the first line of code for the tool?
Nicholas Focil
01:32>> This was about two years ago.
Nathan Latka
01:35Okay. So how have you if you just raised a $150,000 today, how have you funded salaries and things for the past two years?
Funding the Company Through FOMAT Medical Research
Nicholas Focil
01:41>> So this is a byproduct of my company, FOMAT Medical Research, the one I'm CEO for, and that's been it's a product of it. So it's been paying salaries. Self funded self funded, let's say, myself, to
01:53>> answer So sorry, a product.
Nathan Latka
01:54So you have an agency and this is a product of the agency?
Nicholas Focil
01:57>> Correct.
Nathan Latka
01:58Okay. And what does the agency do?
Nicholas Focil
02:00>> Clinical research.
02:02>> We do research for a living.
Nathan Latka
02:04Okay. Interesting. So in 2020, give me a sense of the size of the agency. How much revenue did it do?
Nicholas Focil
02:10>> The FOMAT Medical Research?
Nathan Latka
02:12Whatever the agency is. Yeah.
Nicholas Focil
02:13>> Yeah. So, you know, seven, eight figures.
Nathan Latka
02:18Got it. So so, I mean, what? So, like, 8 to $10,000,000, something like that?
Nicholas Focil
02:22>> Somewhere around those figures. I I mean, I don't wanna enter into too much of those details if if you may if you may.
Nathan Latka
02:28So well, so so tell me what so 8 to $10,000,000 agency revenue, it's it would be hard for me to get distracted from such a big revenue stream to go build some SaaS tool. Why how are you balancing your priorities?
Balancing the Agency and the SaaS Product
Nicholas Focil
02:40>> So I honestly have a phenomenal team. Like, it just, you know, top, top, top notch team. People that see the vision of this company, see the vision of the software, and obviously have some skin in the game as well. And so I I think I lean heavily on them. Also, I know I don't sleep, and I see this future in the health care space needing this. Chronic condition patient, there's a huge need for them. So while
03:11>> I was obviously managing this company, I I noticed this huge elephant in the room and and figured I needed to to solve it or at least try attempt to.
Nathan Latka
03:19So how much capital to date has the agency invested into the SaaS company, febohealth?
Agency Investment Estimated at $500K to $750K
Nicholas Focil
03:26>> I don't know. I don't have any direct number for you. I would I would guess somewhere in $500,000 to $750,000.
Nathan Latka
03:33Okay. 750,000.
Nicholas Focil
03:35>> That's correct.
Nathan Latka
03:36And then the the the obvious question is you have so much revenue coming from the agency. Why go raise a $150,000 from angels? Why not just keep funding it from the agency and keep the equity?
Nicholas Focil
03:45>> Right. That that is a good know, there's multiple reasons, kind of one of the bigger ones, if you will. When you and I actually wrote about it too. We talked about your book recently, and I also wrote about this concept. There's different models of business depending on what type of business, you know. Brick and mortar is you have to solve it certain different ways and technology certain ways. And in this particular space, it's all about quick
04:09>> growth. It's all about, you know, being in the market immediately and being there quick. And for that, you need you need to infuse it with a lot of capital. And you need to have top talent. You need to have top connections. It's a different model of business than the one we do for research, which is more structured. It's more slow moving, which, you know, that's more it's more organic, if you will.
Nathan Latka
04:32Oh, what's going on there, YouTube? Good to see you guys. Now imagine this. You love watching these interviews with SaaS founders, but imagine if we took all of the valuation data out from over 2,807 interviews I've done manually. Saves you a lot of time. Well, we've done this. We've built it into the beautiful interface inside of Founderpath. Check this out. I'll show you how you can access this in a second, but you log in, you connect
04:55your Stripe account, you see your valuation real time. You can see what it changed over the past eighty eight days and even set goals for valuation this year. Now the secret evaluation is there's many different ways to value a SaaS business. So the reason you're gonna see three or four different valuations inside of your Founderpath dashboard, this is all free by the way, is because depending on who's doing the buying of your SaaS company, you're gonna
05:19get a different valuation. A VC is gonna pay a different valuation. Private equity firm is different. If you're gonna do a minority sale, that's different. And if you sell the whole business, that's a different valuation. You can see all those when I hover over here, Right? So the teal is what a VC would pay. Yellow is what private equity and red is if you sold the whole thing outright. Now what's cool about this is this is
05:41not built off random data. Again, you guys hear these interviews on YouTube. All these datas are built from real time valuation data points founders share with us on the show. So traction, 1,200,000 seed round, 3.7 raise. They sold 22% of their business. Go in here and filter by the event. Maybe you only wanna see companies that have sold the whole business. Well, here are a bunch that have been acquired the valuation and the multiple. Maybe you're
06:07going out right now and you're raising your seed round. We'll go in here and look at all this recent seed deals that went down, what they raised, what valuation they raised at, and what percent that they sold. There's never been a larger dataset of SaaS valuations than what you can get now inside of Founderpath. And we're thrilled to bring it to you. All We're right, gonna go back to the YouTube video here in a second, but
06:29if you wanna check this tool out, if you wanna jump in and sign up, you can check it out for free to get your valuation at this link. This link, founderpath.com/products/valuations. Or if you go to founderpath.com and hover over products, click on get your valuation here, and go ahead and sign up to give it a whirl. Again, all that valuation data live right inside the platform. I hope to see you there. Alright. Let's jump back into
06:55the interview. I understand that. But if you have a $10,000,000 agency, it would seem weird that you're out spending your time and energy raising a $150,000, especially when you've already put $750,000 from the agency into the business. It just is I'm I'm missing something here.
Nicholas Focil
07:09>> I it's a different also, by the way, another thing is I'm not the sole owner of the of the agency, as you say. I'm a shareholder, but I'm not the sole owner. I'm the CEO of it. And, you know, it's part of it is part of a package, if you will. Febo, I am the sole owner. Now I've obviously been diluted by by raising, but it is a different it's a different company.
Nathan Latka
07:33I see. So so Nick owns right now about 90, well, I mean, 98% of febo and a couple percentage points go to that people that just put in a $150,000.
Nicholas Focil
07:43>> Plus, have the the employees that have been have given shares. There's a certain amount of stock given for key employees that we've already researched it on the side.
Nathan Latka
07:51I see. Yeah. So an employee stock option pool. How much did you set aside for your ESOP pool? Usually, it's like 10. Well, you're sort of the same?
Nicholas Focil
07:57>> Correct.
Nathan Latka
07:58Alright. Okay. Got it. So 10% ESOP pool, you know, you own 88%, maybe these new investors own one or 2%, something like that.
Nicholas Focil
08:05>> About 3%. Correct.
Nathan Latka
08:07Okay. Got it. So got it. Got it. Got it. Okay. Interesting. Let's talk a little bit more about the why behind this. Right? So give give me an example why you're building. Who who's using it? What are they paying you for? What are they or not paying you yet, but what are they using it for?
One in Three Americans Live With a Chronic Condition
Nicholas Focil
08:19>> So imagine a world that where, you know, one one in three, something some some people say one in two, people suffer chronic conditions in The United States. They're like, well, that's that's crazy because the word chronic condition is is defined loosely. You know, hair loss, which I I do I have, if you will, that's considered a chronic condition. It's not life changing. Right? But when we're thinking of life changing chronic condition, think lupus, Crohn's, Parkinson's, Alzheimer's,
08:44>> those you the modality current modality is you you see your doctor, you get diagnosed, you you get on a treatment plan, and you then check-in with your doctor maybe every four to six months. But there's a direct dependency on you and the physician, you and the infrastructure, you and the system, if you will, every four to six months. What we're trying to what we've noticed is depending on the size of the disease, there's more or less
09:07>> attention on that particular condition. So, why depend entirely on the condition on the system? So what we wanna do is create a system where you depend on yourself. So giving you all the tools where you start having agency agency on yourself, and you have to start taking a little bit of control over. So meaning tools like simple things like, for example, pill reminder. That's an easy one. Right? But then you're entering into things where you can
09:33>> do crowdsourcing. So think of pill reminder, but then if I have a room of 10,000 people with lupus, wouldn't you think that I now know people with lupus that have these kind of general kind of variables are taking this medication. It's working. Here are the side effects. Now why couldn't I have a crowdsourced solution to that where I'm now see compare myself. Well, a person across the state is also taking this medication, but they're taking in
10:00>> combination with this other medication. So now I go to the doctor, and I'm like, hey. You know, twenty percent of the population is taking it with this Otsu thing, and it's working really well compared to what I'm doing. What what are your thoughts on it? So now you've kind of empowered the patient to push it to the doctor. The doctor will be like, no. I I don't recommend that
Nathan Latka
10:16because you are Isn't it very hard to convince people to tell everyone else what medications they're taking, which is critical for you to understand and tell a neighbor that someone across the state is using another medication, but you you tell them, obviously, you try and keep it anonymous. But isn't it hard to get people to opt into that?
Anonymous and Encrypted: Solving the Privacy Problem
Nicholas Focil
10:30>> So, yes. A 100%. So there's a few things we're doing. A, entirely anonymous, entirely encrypted, double encrypted. You don't need to even put a name to it. You don't need to put an email. Like, you don't even have to create you can you can have it be entirely fake where you can put a wall, like, can put a different picture. We don't request any information from you. It's entirely anonymous and double encrypted. So that's kind of
10:52>> to help that part, but also there's multiple ways. So you said that one of them is the medication, which you just said, which we're just talking about, but there's other things like symptom tracker. So you put your symptoms, right? So let's say you have fibromyalgia, and let's say you woke up with headaches, or you're waking up with different bloated, and you start tracking your symptoms. If we're comparing patients with Crohn's with these symptoms and across The
11:16>> States, the same thing, we can now compare variables. So it's a lot of crowdsourcing with your own intel being put in.
Nathan Latka
11:23I know. I'm just saying you have a very, very serious chicken and egg problem here. I mean, I just bought an Apple Watch, And despite the fact that it can give me my ECG, my heart rate, to my steps, everything, I'm not wearing it right now because I find it annoying. I still don't know if I want give Apple all of my information. I can guarantee Apple security is tighter than yours because their dev team is
11:41infinitely bigger. I just think I mean, how do you get people to sign up for this?
14,000 Downloads and the News Feed Flagship Tool
Nicholas Focil
11:46>> So, again, yes, you're you're absolutely right. And we're right now about 14,000 downloads and growing. We just opened up the App Store June 2021. So we're about a year and two months into it. Sorry. And I'm a little bit off on my numbers there. A year and seven months into it. But we're just we just ranged. We just closed the round. So we're now officially up until that point and entirely organic. The reason why is that
12:14>> we have multiple tools and each tool like, for example, I don't use all of them. I only use, like, one of the easiest ones, which I think most people can get behind of is our news tool. So let's say you have lupus and, Japan recently approved a drug for the treatment of lupus. That drug is not approved in The United States. That that article, this is a patent pending patent pending algorithm, is that article is being
12:42>> translated to English and it's getting pushed to you in real time. So you get to read it and you tell the doctor about the art. So you can, like, immediate news feed on all things lupus from a validated source. And those are easy. Just like you're following CNN every morning, you follow your news feed on whatever condition you have, and it gets pushed to you. You read whatever you want. You don't read whatever you don't want,
13:02>> and then you can comment on it if you want. So that's a generally easy topic to do, and that's where we see that that's one of our flagship tools, if you will. And, again, there's a crowdsourcing concept to that as well.
Nathan Latka
13:14I mean, doesn't Apple just kill you or any watch just kill you in a year?
Nicholas Focil
13:19>> So we I mean, not not really. So Garmin, for example. Garmin reached out to us for a partnership. So we they if you have Garmin, you can integrate it to our app, and it pulls that information to, like, pre fab pre fill some of the information. In our tool for the for the news, for example, our steering committee says it's articles they can't find on Google yeah. Sure. You can find it on Google, by the way.
13:42>> I'm not saying you can. It's like we're but you'll have to go, like, page 17 to find it. You know, it's published by Harvard or whatever. They they those are not gonna be high targeted words. It's gonna be more so, like, maybe something that Google thinks is more important for you to read while we're
Nathan Latka
13:56I'm just saying, Nick, what I I am not seeing a clear moat here of something that's so unique to your experience, your background that you can accurately and predictably, like, defend against Apple just adding a little thread in the Apple Watch Health app that says, oh, we told you you have lupus. Here is the Japanese. Like, here's a new a Google Alerts little system for lupus. I'm I don't see an advantage that you have over everybody
14:16else.
Nicholas Focil
14:17>> I guess my clearest advantage is we're I mean, it's not it's a it's a market focus, if you will. Apple, for them to move the needle, they have to focus on a larger audience. And we are not focused on a larger or, like, you're not my customer. I mean, I don't know whether or not I'm assuming here, but we're our customers are the chronic condition patients, which are, like, life changing diseases. We're doing we're doing tools
14:42>> that are very specific to that particular condition.
Nathan Latka
14:45I see. I see.
Nicholas Focil
14:46>> Yeah. Log, for example.
Nathan Latka
14:49Okay. So how do you obviously, one one day you have to make money on this. Otherwise, you're gonna sell your all company into VCs and have nothing left. Right? So how do you make money from this?
Path to Monetization: 100,000 User Threshold
Nicholas Focil
14:56>> So in two to three years, we'll start opening it up. We're looking to get to a minimum threshold about a 100,000 users. And at that point,
Nathan Latka
15:04when you How many downloads last month?
Nicholas Focil
15:07>> I don't I don't have that data. I do know that we had last week, so I can kind of extrapolate if you will, about 200 downloads, so about 800, if you will, probably. We're just, as as of yesterday, turned on the engine to be paid advertising. So we do expect a a pretty large uptick on on downloads.
Nathan Latka
15:28How much do you think you're gonna spend to get one new download?
Nicholas Focil
15:32>> We're spending about the national average is $2.80. We're right now at, like, $1.70 something.
Nathan Latka
15:41So what's the sample size though to get the $1.70 number? How much of your $150,000 that you just raised have you already spent to test ads?
Paid Advertising Launched February 1, 2022
Nicholas Focil
15:46>> Zero. The of of the money that we've raised, we haven't spent any money yet. We we that were launched as of yesterday to February 1 is when Okay. So you
Nathan Latka
15:54don't know what your CAC is yet. You're guessing. But you're gonna try and figure that out.
Nicholas Focil
15:58>> That that we've been doing it, but through FOMAT, if you will. We've been spending
Nathan Latka
16:01Through what?
Nicholas Focil
16:02>> FOMAT is the parent company, the agency, as you call it.
Nathan Latka
16:06I see. Got it. So how much have you spent via FOMAT driving downloads of the app?
Nicholas Focil
16:11>> I would say somewhere around maybe $10,000 to $20,000 worth of advertising.
Nathan Latka
16:16Okay. Got it. Is that included in the $750,000 the agency has put into the business?
Nicholas Focil
16:19>> Yeah. That is correct.
Nathan Latka
16:20And you didn't mention the agency on the cap table earlier. So how did why the agency put $750k into the app if they don't own any equity?
Nicholas Focil
16:27>> They do own equity. They do own some equity. I I
Nathan Latka
16:30I imagine it's a fairly big chunk of equity, right, if they put in 750 k?
Nicholas Focil
16:36>> Not it is a percent. It it's not substantial, but it is as you also have to remember is I'm also part owner of the agency. So it's part of my bonus structure, if you will. Instead of receiving an extra bonus, I receive more shares of of it, if you will. I I I opted out of bonus to get more shares of febo.
Nathan Latka
16:57I opted out of the bonus to get more shares of febo. So you told me earlier right now there's an ESOP pool of 10%, investors own 3%, and you own 87%. That's a 100%. So I don't know where there's room left for the agency to own anything.
Cap Table Breakdown: Founder, Agency, ESOP, Investors
Nicholas Focil
17:10>> So I don't own 87. I own 82. The agency owns 5%. I I
Nathan Latka
17:15Oh, I see. So you basically were able to get the agency to commit to $750,000 for 5% of the business?
Nicholas Focil
17:20>> That's correct. Over a period of two and three years.
Nathan Latka
17:23I see. I see. Interesting. Very cool. Kudos to to you for jumping out, using agency to learn, and launching your own thing where you have way more equity upside. I hope you can get it to market and generate revenue, and congrats on closing the seed. We're out of time, though. So let's wrap up here with the famous five. Number one, favorite book.
Famous Five: Books, Sleep, and Lessons Learned
Nicholas Focil
17:39>> My favorite book?
Nathan Latka
17:43Sure.
Nicholas Focil
17:44>> That's a hard that's a hard one that I'm reading right now is about VR, technology and healthcare space. Things are really Number
Nathan Latka
17:49two, is there a CEO you're following or studying?
Nicholas Focil
17:53>> I would say super cliche, Bill Bill Gates. I think he's just innovative in multiple spaces.
Nathan Latka
18:00Number three, what's your favorite online tool for building febo?
Nicholas Focil
18:04>> I think a powerful tool in Asana from project management perspective.
Nathan Latka
18:08Number four, how many hours of sleep do get every night?
Nicholas Focil
18:10>> Five to six. Five.
Nathan Latka
18:12And what's your what's your situation? Married, single, kids?
Nicholas Focil
18:15>> Married, two kids, happily married.
Nathan Latka
18:17That's awesome. How old are you?
Nicholas Focil
18:19>> 35.
Nathan Latka
18:20Last question. Something you wish you knew when you were 20.
Nicholas Focil
18:23>> I'm sorry?
Nathan Latka
18:24Something you wish you knew when you were 20.
Nicholas Focil
18:26>> Something that I was wishing when I was 20.
Nathan Latka
18:28Something you wish you knew when you were 20.
Nicholas Focil
18:32>> That yeah. Oh, that's a group. That's a phenomenal question. How to raise, I suppose. Because I yeah. How to raise appropriately.
Nathan Latka
18:39Guys, there you have it. Launch of an agency consulting directly in the health care space, doing eight to ten million bucks in revenue. He wasn't the sole owner, though. The agency decided, you know what, I want to spin this out and launch a SaaS app. He now owns over 80% of the SaaS app. This goes to seed round to start driving growth. They have 10,000, 14,000 downloads, helping patients, chronic patients understand updates, innovations in their space
19:00so they can test new treatments, pattern recognize across more other people with the same chronic disease and try and improve their health. We'll see what happens next. Nick, thanks for taking us to the top.
Nicholas Focil
19:10>> Thank you. Thank you actually for that interview. I really appreciate it. It was a great time.
Nathan Latka
19:15One more thing before you go. We have a brand new show every Thursday at 1PM central. It's called Shark Tank for SaaS. We call it deal or bust. One founder comes on, three hungry buyers, they try and do a deal live, and the founder shares back end dashboards, their expenses, their revenue, ARPU CAC, LTV, you name it, they share it and the buyers try and make a deal live. It is fun to watch every Thursday 1PM
19:40Central. Additionally, remember these recorded Founder interviews go live. We release them here on YouTube every day at 2PM Central. To make sure you don't miss any of that, make sure you click the subscribe button below here on YouTube, the big red button and then click the little bell notification to make sure you get notifications when we do go live. I wouldn't want you to miss breaking news in the SaaS world, whether it's an acquisition, a big
20:03fundraise, a big sale, a big profitability statement or something else. I don't want you to miss it. Additionally, if you wanna take this conversation deeper and further, we have by far the largest private Slack community for B2B SaaS founders. You want to get in there. We've probably talked about your tool if you're running a company or your firm if you're investing. You can go in there and quickly search and see what people are saying. Sign up
20:24for that at nathanlatka.com/slack. In the meantime, I'm hanging out with you here on YouTube. I'll be in the comments for the next thirty minutes. Feel free to let me know what you thought about this episode and if you enjoyed it, click the thumbs up. We get a lot of haters that are mad at how aggressive I am on these shows, but I do it so that we can all learn. We have to counter those people. We
20:44got to push them away. Click the thumbs up below to counter them and know that I appreciate your guys'support. Alright, I'll be in the comments. See you.